Graphite Bio, Inc.
NASDAQ: GRPH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kimberlee Cobleigh Drapkin CPA
- Employees
- 6
- Headquarters
- South San Francisco, United States
- IPO year
- 2021
- Market cap
- $185.2M
- Website
- https://www.graphitebio.com
Loading GRPH…
Loading profile data…Frequently asked questions about GRPH
What does Graphite Bio, Inc. (GRPH) do?
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underly...
Where does GRPH trade?
Graphite Bio, Inc. (GRPH) trades on the NASDAQ Global Market.
What sector is GRPH in?
Graphite Bio, Inc. (GRPH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Graphite Bio, Inc.?
Kimberlee Cobleigh Drapkin CPA is the chief executive officer of Graphite Bio, Inc. (GRPH).
Where is Graphite Bio, Inc. headquartered?
Graphite Bio, Inc. is headquartered in United States.
Does GRPH pay a dividend?
Yes — Graphite Bio, Inc. (GRPH) paid a trailing twelve-month dividend of USD 2.06 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did GRPH go public?
Graphite Bio, Inc. (GRPH) completed its initial public offering in 2021.